<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567578</url>
  </required_header>
  <id_info>
    <org_study_id>YH12852-201</org_study_id>
    <nct_id>NCT02567578</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Dose-finding Phase 2 Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled dose-finding phase 2&#xD;
      trial to evaluate the efficacy and safety of YH12852 in patients with functional dyspepsia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will be randomized into one of 4 groups; YH12852 0.1 mg, 0.25 mg, 0.5 mg,&#xD;
      or placebo at the same ratio and will be administered investigational products orally, twice&#xD;
      daily for 4 weeks and followed up for 2 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    due to dose re-selection&#xD;
  </why_stopped>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of OTE (Overall Treatment Efficacy) responders</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of OSS responders</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate for 8 functional dyspepsia symptoms</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from basline in NDI QoL score</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>YH12852 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 0.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>twice daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 0.1 mg</intervention_name>
    <arm_group_label>YH12852 0.1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 0.25 mg</intervention_name>
    <arm_group_label>YH12852 0.25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 0.5 mg</intervention_name>
    <arm_group_label>YH12852 0.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must be willing and able to provide written informed consent.&#xD;
&#xD;
          2. BMI of &lt; 35 kg/m2&#xD;
&#xD;
          3. Patients experiencing one or more of functional dyspepsia symptoms beginning at least&#xD;
             6 months prior according to Rome III criteria, with the symptom(s) evident over the&#xD;
             last 3 months at the time of screening&#xD;
&#xD;
          4. Patients with no evidence of organic lesions based on upper GI endoscopy, which could&#xD;
             be the cause of dyspeptic symptoms&#xD;
&#xD;
          5. Women of childbearing potential (WOCBP) must have a negative pregnancy test result at&#xD;
             the screening visit and use an adequate method of contraception to avoid pregnancy&#xD;
             throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or breastfeeding.&#xD;
&#xD;
          2. Women with a positive pregnancy test result on enrollment or prior to investigational&#xD;
             product administration.&#xD;
&#xD;
          3. Subjects with a history of surgery that could affect gastrointestinal motility&#xD;
&#xD;
          4. Subjects with inflammatory bowel disease&#xD;
&#xD;
          5. Clinically significant chronic infection (eg. AIDS, etc), or significant medical or&#xD;
             psychiatric illness.&#xD;
&#xD;
          6. Serious cardiovascular disease (including QT prolongation defined as QTc interval â‰¥&#xD;
             450msec) or respiratory disease&#xD;
&#xD;
          7. History of alcohol or drug abuse within the previous one year.&#xD;
&#xD;
          8. Subjects with mental illness (e.g. schizophrenia, dementia etc) that may render the&#xD;
             inability to complete the study&#xD;
&#xD;
          9. Physical and Laboratory Test Findings&#xD;
&#xD;
         10. Administration of any other investigational product or participation in other clinical&#xD;
             trials within 3 months prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Poong Lyul Lee, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung seoul hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung seoul hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>YH12852</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

